Black Diamond Therapeutics
BDTX
80 hedge funds and large institutions have $968M invested in Black Diamond Therapeutics in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 4 closing their positions.
400% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 4
123% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 13
74% more capital invested
Capital invested by funds: $556M → $968M (+$412M)
23% more funds holding
Funds holding: 65 → 80 (+15)
2.34% more ownership
Funds ownership: 62.09% → 64.43% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$9.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.45M |
| 3 |
BlackRock
New York
|
+$6.8M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$6.53M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6M |
| 2 |
AG
Artal Group
Luxembourg
|
-$5.52M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.75M |
| 4 |
Goldman Sachs
New York
|
-$2.69M |
| 5 |
JP Morgan Chase
New York
|
-$982K |
BDTX Hedge Fund Activity: Q2 2020 in Review
80 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q2 2020, worth a combined $968M — up 74% from $556M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new BDTX positions and 4 closed out — a net gain of 16 holders — while 29 added to existing stakes and 13 trimmed.
The largest buyer was Wells Fargo, adding an estimated $9.8M. The largest seller was Fidelity Investments, cutting an estimated $6M.
- 80 institutional investors held Black Diamond Therapeutics (BDTX) as of Q2 2020, up from 65 in Q1 2020.
- Funds reported $968M of Black Diamond Therapeutics stock for Q2 2020, up 74% quarter-over-quarter.
- 20 funds opened new Black Diamond Therapeutics positions in Q2 2020 and 4 closed out, a net change of +16 holders.
- The largest Black Diamond Therapeutics buyer in Q2 2020 was Wells Fargo, an estimated $9.8M added.
- The largest Black Diamond Therapeutics seller in Q2 2020 was Fidelity Investments, an estimated $6M sold.
Based on aggregated 13F filings for Q2 2020.